Sebela Pharmaceuticals

FDA Premarket Approval gives Implantica a US commercialization pathway for RefluxStop, a gastroesophageal reflux disease implant backed by long-term clinical evidence and designed to avoid encircling the esophagus. Representative image.

Pharma & Biotech

Sebela Pharmaceuticals reports positive ACG 2026 data for tegoprazan in reflux disease

by Pallavi Madhiraju
October 12, 2026
0 Comments

Sebela's tegoprazan improves heartburn and regurgitation in Phase 3 NERD data. Examine efficacy, FDA review and competition.

Read More

Organon & Co. licenses MIUDELLA copper IUD what this changes in the U.S. hormone-free contraception market

Medical Devices & Diagnostics

Organon & Co. strengthens LARC strategy with MIUDELLA license from Sebela Pharmaceuticals

by Pallavi Madhiraju
February 28, 2026
0 Comments

Organon & Co. licenses MIUDELLA copper IUD. Explore what this means for hormone-free contraception and LARC competition. Read the analysis.

Read More